Comprehensive molecular diagnostics closer for more patients thanks to price reduction
Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This price reduction will make broad molecular diagnostics accessible to more patients with cancer.
Robert Jan Lamers, Managing Director of Hartwig Medical Foundation:
“Every patient with cancer deserves access to the best possible diagnostics and treatment. By lowering the price, molecular diagnostics become available to more patients, supporting clinicians in selecting the bestt treatment options for their patients.”
The price reduction has been made possible by the implementation of the Illumina NovaSeq X-Plus sequencing platform, on which WGS has been validated for diagnostic use. Hartwig will also continue to contribute to the costs to further promote the use of WGS for patients.
OncoAct WGS can be used as reimbursed diagnostics for cancer of unknown primary (CUP/PTO), non-small cell lung cancer (NSCLC), and for determining responsiveness to NTRK-inhibitors, regardless of tumor type, subject to agreement with health insurers.
For AYA patients (Adolescents and Young Adults), OncoAct WGS remains free of charge for hospitals as part of the KWF-funded GENAYA-project. More information is available at GENAYA.nl.
Do you have any questions? Please consult with us.
You read an article in the category Whole genome sequencing. You may also be interested in Hartwig Medical Foundation, Lab process, Molecular diagnostics, OncoAct All newsAlso read
Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed
Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough …
Hartwig visit to Jackson Laboratory in Farmington, CT
For interpretation of molecular results, Hartwig relies on the CKB resource that has been developed by The Jackson Laboratory, and …
Hartwig tools now available as a nextflow nf-core pipeline called oncoanalyser
The University of Melbourne Centre for Cancer Research (UMCCR) Genomics Platform Group, led by Professor Oliver Hofmann, has collaborated with …
We are proud that we succeeded in implementing the complete DNA test in standard of care diagnostics, together with Hartwig Medical Foundation. Moreover, the test produces vital information for a learning healthcare system in oncology. We will be able to treat future patients even more effectively.